Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions
Open Access
- 13 November 2012
- journal article
- research article
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 7 (1) , 121
Abstract
Background: The identification of malignant cells in effusions by conventional cytology is hampered by its limited sensitivity and specificity. The aim of this study was to investigate the value of fluorescence in situ hybridization (FISH) as adjuncts to conventional cytologic examination in patients with malignant pleural effusions. Methods: We conducted a retrospective cohort study of 93 inpatients with pleural effusions (72 malignant pleural effusions metastatic from 11 different organs and 21 benign) over 23 months. All the patients came from Chinese northeast areas. Aspirated pleural fluid underwent cytologic examination and fluorescence in situ hybridization (FISH) for aneuploidy. We used FISH in single-colour or if appropriate in dual-colour evaluation to detect chromosomal aberrations (chromosomes 7, 11, and 17) in effusion cells as markers of malignancy, to raise the diagnostic yield and identified the efficiency by diagnostic biopsy. Predominant cytogenetic anomalies and patterns of intratumor cytogenetic heterogeneity were brought in relation to overall survival rate. Results: Cytology alone confirmed malignant pleural effusions in 45 of 72 patients (sensitivity 63%), whereas FISH alone positively identified 48 of 72 patients (sensitivity 67%). Both tests had high specificity in predicting benign effusions. If cytology and FISH were considered together, they exhibited 88% sensitivity and 94.5% specificity in discriminating benign and malignant effusions. Combined, the two assays were more sensitive than either test alone. Although the positive predictive value of each test was 94.5%, the negative predictive value of cytology and FISH combined was 78%, better than 47% and 44% for FISH and cytology alone, respectively. There was a significantly prolonged survival rate for patients with aneuploidy for chromosome 17. Conclusions: FISH in combination with conventional cytology is a highly sensitive and specific diagnostic tool for detecting malignant cells in pleural effusions . The high sensitivity and specificity may be associated with geographic area and race. Simple numeric FISH anomalies may be prognostic.Keywords
This publication has 29 references indexed in Scilit:
- Chromosomal Aberrations in Bladder Cancer: Fresh versus Formalin Fixed Paraffin Embedded Tissue and Targeted FISH versus Wide Microarray-Based CGH AnalysisPLOS ONE, 2011
- Interphase fluorescence in situ hybridization analysis detects a much higher rate of thyroid tumors with clonal cytogenetic deviations of the main cytogenetic subgroups than conventional cytogeneticsCancer Genetics, 2011
- Management of Pleural Effusion in the Cancer PatientSeminars in Respiratory and Critical Care Medicine, 2010
- Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer PatientsClinical Cancer Research, 2010
- Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arraysInternational Journal of Cancer, 2009
- Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusions of patients with and without malignancy: By interphase FISH techniqueCancer Biology & Therapy, 2005
- Intraoperative Pleural Lavage: Is It a Valid Prognostic Factor in Lung Cancer?The Annals of Thoracic Surgery, 2005
- FISH cytogenetics and prognosis in breast and non-small cell lung cancersCytometry, 2004
- Combination of Cytology, Fluorescence In Situ Hybridization for Aneuploidy, and Reverse-Transcriptase Polymerase Chain Reaction for Human Mammaglobin/Mammaglobin B Expression Improves Diagnosis of Malignant EffusionsJournal of Clinical Oncology, 2004
- Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cellsMutation Research Letters, 1995